---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-016454"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:12:00.887954+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Galectin Therapeutics reports FY2023 net loss of $44.8M; cash runway through March 2025

## Summary
- Net loss applicable to common stockholders of $44.8M ($0.74/share) vs $38.9M ($0.65/share) in FY2022.
- Cash and equivalents $25.7M at Dec 31; plus $20M available credit line and new $10M facility from chairman.
- NAVIGATE Phase 2b/3 trial for belapectin in MASH cirrhosis fully enrolled (357 patients); interim analysis readout expected Q4 2024.
- Appointed Benjamin S. Carson, Sr., M.D. to Board of Directors.
- Fourth DSMB meeting authorized continuation of NAVIGATE trial without modifications.

## SEC filing metadata
- accession: 0001140361-24-016454
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036124016454/0001140361-24-016454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036124016454/ef20025022_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-016454
- JSON: https://secwatch.observer/filing/0001140361-24-016454.json
- Plain text: https://secwatch.observer/filing/0001140361-24-016454.txt

## Key facts
- Earnings Releases
  GALECTIN THERAPEUTICS INC reported the year ended December 31, 2023 results: net income net loss applicable to common stockholders of $44.8 million, or ($0.74) per share, EPS $(0.74).
  - Period: the year ended December 31, 2023
  - Net income: net loss applicable to common stockholders of $44.8 million, or ($0.74) per share
  - EPS: $(0.74)
  - Result: reported results
  source text: For the year ended December 31, 2023, the Company reported a net loss applicable to common stockholders of $44.8 million, or ($0.74) per share, compared to a net loss applicable to common stockholders of $38.9 million, or ($0.65) per share for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133416/000114036124016454/0001140361-24-016454-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.